FDA Approves Orilissa (elagolix) for Moderate to Severe Endometriosis Pain
- Barber J. US approves AbbVie, Neurocrine Biosciences' Orilissa for pain associated with endometriosis. FirstWorld Pharma. http://www.firstwordpharma.com/node/1580636#axzz5MGcALSAD. Published July 24, 2018. Accessed July 26, 2018.
- AbbVie Receives U.S. FDA Approval of ORILISSA™ (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis. AbbVie Pressroom. https://news.abbvie.com/news/abbvie-receives-us-fda-approval-orilissa-elagolix-for-management-moderate-to-severe-pain-associated-with-endometriosis.htm. Published July 24, 2018. Accessed July 26, 2018.
- Prescribing Information. RXAbbVie. https://www.rxabbvie.com/pdf/orilissa_pi.pdf. Accessed March 7, 2019.
- Orilissa. Orilissa. https://www.orilissa.com/. Accessed March 7, 2019.